Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts.
Alnylam Pharmaceuticals announced its first discovery-focused AI deal Wednesday, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts.
Alnylam …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
Legend Biotech emerged as a rare market winner
AI-Powered drug discovery could transform treatment development for Alzheimer’s, Parkinson’s and other brain disorders.
Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics
Apoha, a startup using building AI based on new liquid 'wave form' data, emerges from stealth with $36 million Series A round | Fortune
Apoha, a startup using building AI based on new liquid 'wave form' data, emerges from stealth with $36 million in funding | Fortune
